Biomx raises $12M to advance phage therapy for CF infections
Biomx has raised $12 million in financing to advance BX004, a phage therapy being developed to treat bacterial infections — specifically, ones caused by Pseudomonas aeruginosa, known as P. aeruginosa for short — in people with cystic fibrosis (CF). The funding comes from investors purchasing the company’s stock,…